Merck faces sales challenges in China while simultaneously seeking FDA approval for new drugs.
2 reports, 1 independent
Updated Sep 22
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Merck faces sales challenges in China while simultaneously seeking FDA approval for new drugs.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Keep exploring
The entities involved
-
China
cultural region, ancient civilization, and nation in East Asia; mostly refers to the People's Republic of China in political situation and rarely refers to the Republic of China
-
Merck
public company in Indonesia
- FDA
Related events
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.
- EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.
- FDA approved Rasonque for pancreatic cancer, while Revolution Medicines evaluates therapy with Merck's Keytruda and compares its market cap to Eli Lilly.
- The FDA granted Orphan Drug Designation to sovleplenib, a drug associated with HUTCHMED, which operates in China.